List of Excipients in Branded Drug REGLAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	REGLAN	metoclopramide hydrochloride	16590-906	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	REGLAN	metoclopramide hydrochloride	16590-906	MAGNESIUM STEARATE
STAT RX USA LLC	REGLAN	metoclopramide hydrochloride	16590-906	MANNITOL
STAT RX USA LLC	REGLAN	metoclopramide hydrochloride	16590-906	STEARIC ACID
ANI Pharmaceuticals Inc	REGLAN	metoclopramide hydrochloride	62559-165	ALUMINUM OXIDE

Reglan Excipient Strategy and Commercial Opportunities for Metoclopramide

Last updated: August 6, 2026

Reglan is the legacy brand for metoclopramide, a dopamine D2 receptor antagonist used for diabetic gastroparesis and short-term gastroesophageal reflux disease that has not responded to conventional treatment. Its commercial opportunity is no longer based on branded patent exclusivity. The opportunity is in differentiated formulations, excipient-driven usability, supply reliability, and targeted 505(b)(2) products.

The principal commercial constraints are metoclopramide’s boxed warning for tardive dyskinesia, dose-duration limits, low active-ingredient dose, and the availability of inexpensive generic tablets and injections. Excipient innovation can support new dosage forms, pediatric or geriatric administration, palatability, preservative reduction, and controlled exposure, but it does not remove the drug’s neurological safety risks.[1]

What is Reglan and how is metoclopramide regulated?

Reglan contains metoclopramide hydrochloride, commonly supplied as oral tablets, oral solution, and injectable products. The FDA-approved indications include:

• Short-term treatment of symptomatic, documented gastroesophageal reflux disease in adults who fail conventional treatment.
• Treatment of acute and recurrent diabetic gastroparesis in adults.
• Injection use in selected clinical settings, including diabetic gastroparesis and certain gastrointestinal diagnostic or procedural applications, depending on product labeling.[1]

Metoclopramide increases upper gastrointestinal motility and accelerates gastric emptying. Its central dopamine antagonism creates the principal safety issue: tardive dyskinesia, which can be irreversible. FDA labeling recommends avoiding treatment longer than 12 weeks except in rare cases where therapeutic benefit outweighs risk.[1]

What is the FDA status of Reglan?

Reglan and metoclopramide products are approved under the Federal Food, Drug, and Cosmetic Act. The original Reglan products are legacy products, and generic metoclopramide products are widely available.

The FDA has required boxed-warning language concerning tardive dyskinesia and has taken action against unapproved or improperly marketed metoclopramide products. Any new formulation must address the approved indication, route of administration, dosing, labeling, and safety monitoring requirements rather than relying solely on excipient changes.[1,2]

What excipients are used in Reglan products?

Excipient composition varies by manufacturer, strength, dosage form, and jurisdiction. The relevant excipient categories include fillers, binders, disintegrants, lubricants, coatings, sweeteners, flavors, solvents, preservatives, and pH modifiers.

Oral tablets

Immediate-release metoclopramide tablets generally use conventional solid-dose excipients. Typical functional categories include:

Excipient function	Commercial purpose
Diluent or filler	Supports tablet weight and compression
Binder	Improves granule and tablet integrity
Disintegrant	Promotes breakup after administration
Lubricant or glidant	Supports manufacturing and ejection
Film coating	Improves swallowability, identification, and stability
Colorant	Enables product differentiation and dose identification

The main opportunity is not a novel inactive ingredient by itself. It is a better-performing tablet that improves swallowability, reduces tablet burden, or supports a new regulatory pathway.

Oral solution

Liquid metoclopramide products may contain purified water, sweeteners, flavors, pH adjusters, viscosity modifiers, and antimicrobial preservatives. The commercial performance of an oral solution depends heavily on:

• Chemical stability across the shelf-life period.
• Palatability and aftertaste.
• Dose-measuring accuracy.
• Preservative tolerability.
• Compatibility with dosing syringes and administration devices.
• Microbial control after opening.

Metoclopramide’s bitter taste makes flavor and taste-masking strategy material. A multi-part flavor system, ion-pairing approach, cyclodextrin complex, or polymeric taste-masking system could improve adherence, particularly for patients who cannot swallow tablets.

Injectable products

Injectable metoclopramide products require control of sterility, endotoxin, particulate matter, pH, osmolality, container compatibility, and degradation products. Excipients may include water for injection, sodium chloride, pH-adjusting agents, and, depending on the formulation, preservatives.

Preservative-free single-dose presentations could have commercial value in hospitals and procedural settings. The opportunity is strongest where institutional buyers prioritize ready-to-administer packaging, reduced preparation steps, and compatibility with automated dispensing or infusion systems.

What excipient strategies have the strongest commercial potential?

The strongest strategies address a specific administration problem and create a defensible regulatory or market position.

Taste-masked oral liquid

A palatable oral liquid could target adults with gastroparesis who have difficulty swallowing, patients requiring enteral administration, and selected pediatric or adolescent populations where an approved indication and dosing program support use.

The formulation must preserve dose uniformity at low concentrations. Taste masking must not impair release, cause sedimentation, clog oral syringes, or create unacceptable chemical instability. A ready-to-use product would compete against generic solutions and compounded preparations on consistency, convenience, and quality control.

Orally disintegrating tablet

An orally disintegrating tablet could target patients with nausea, impaired gastric function, dysphagia, or limited access to water. The formulation challenge is balancing rapid disintegration with acceptable taste and mechanical strength.

A conventional ODT would face a relatively weak differentiation case if it merely changes administration without improving adherence or addressing a recognized patient segment. A 505(b)(2) strategy could be stronger if the product demonstrates meaningful clinical or pharmacokinetic advantages, such as faster administration or improved use in patients unable to swallow.

Modified-release formulation

A modified-release formulation could reduce dosing frequency or smooth peak concentrations. Its commercial rationale is less straightforward because metoclopramide is subject to dose and duration restrictions driven by neurological safety, not only by convenience.

A controlled-release product would require careful evaluation of:

• Total exposure and peak concentration.
• Gastric emptying variability.
• Food effects.
• Dose proportionality.
• Risk of accumulation.
• Whether prolonged exposure could worsen extrapyramidal or tardive dyskinesia risk.

A sustained-release formulation that increases cumulative exposure without a clear safety advantage would face significant regulatory and commercial resistance.

Preservative-free injection

A preservative-free injectable product in single-dose vials, prefilled syringes, or ready-to-use containers could compete in hospitals and ambulatory care. The value proposition would be operational:

• Reduced compounding activity.
• Lower preservative exposure.
• Standardized dose presentation.
• Faster administration.
• Better compatibility with pharmacy automation.

Container closure and extractables/leachables work would be central. The product would also need to compete against low-cost generic ampules and vials.

Low-volume, high-concentration liquid

A concentrated oral solution could reduce administration volume for adults and older patients. The formulation must avoid dosing errors, particularly where the delivered volume becomes too small for reliable measurement.

A commercial product would need an oral syringe, clear concentration labeling, and human-factors validation. High concentration can increase palatability and precipitation risks, so the excipient system must be designed around the target strength rather than simply reducing water content.

How many patents protect Reglan and metoclopramide?

No meaningful active patent estate is generally associated with the original metoclopramide active ingredient or legacy Reglan products in the United States. Metoclopramide was approved decades ago, and the core compound, conventional tablets, and basic injectable presentations are outside their original patent terms.

Protection category	Current commercial relevance
Original compound patent	Expired
Legacy Reglan product patents	Expired or no longer commercially significant
Conventional generic tablet patents	Generally not a material barrier
Formulation patents	May arise for new products, but depend on claim scope and filing date
Method-of-use patents	Potentially relevant only for narrowly defined new uses
Regulatory exclusivity	No general current exclusivity for conventional metoclopramide products

Patent risk would arise primarily from a newly developed formulation, delivery system, manufacturing process, or narrowly claimed use. A sponsor cannot assume that an excipient substitution creates patentable subject matter. The invention would need to show a defensible technical relationship between the excipient system and an unexpected or commercially meaningful result.

When does Reglan lose exclusivity?

Reglan has already lost its principal market exclusivity. Generic metoclopramide products compete in oral and injectable dosage forms, subject to product-specific FDA approvals and supply conditions.

A new metoclopramide product could obtain regulatory exclusivity under a new drug application pathway if it qualifies for a statutory exclusivity category. A 505(b)(2) application may rely partly on FDA findings for a listed drug while supporting a formulation, dosage form, route, or other modification with new data.[3]

Potential exclusivity categories include:

• Three years for certain applications containing new clinical investigations essential to approval.
• Five years for a new chemical entity, which is generally unavailable for metoclopramide because the active ingredient is well established.
• Pediatric exclusivity, if statutory requirements are satisfied.
• Orphan-drug exclusivity only for an eligible rare disease indication, which is not inherent in an excipient reformulation.

Regulatory exclusivity would not prevent all competition if other sponsors can rely on an existing reference product through an independent pathway.

What is the Orange Book status of Reglan?

The FDA Orange Book identifies approved drug products and patent or exclusivity information submitted for listed products.[4] Legacy Reglan and generic metoclopramide listings should be evaluated by dosage form and strength rather than by brand name alone.

For conventional metoclopramide products, the key Orange Book conclusion is that the market is primarily generic. A sponsor assessing a new product should review:

1. Active listings for metoclopramide tablets, solutions, and injections.
2. Reference listed drug designations.
3. Any patent certifications or exclusivity attached to a particular listed product.
4. Therapeutic-equivalence codes for competing products.
5. Discontinued-product status and historical listing changes.

An Orange Book review is essential before selecting a 505(b)(2) reference product. The relevant reference product may not be the legacy Reglan brand if the intended product relies on a different formulation or dosage form.

Which companies are challenging Reglan with generic metoclopramide?

Generic competition comes from multiple manufacturers and labelers rather than a single challenger. The competitive set can change because of product discontinuations, contract manufacturing arrangements, shortages, and wholesaler purchasing decisions.

The principal competitors are generic manufacturers of:

• Metoclopramide tablets.
• Metoclopramide oral solution.
• Metoclopramide injection.
• Hospital-use presentations and institutional packages.

Paragraph IV litigation is not the central current issue for conventional metoclopramide. The active-ingredient and legacy product patent landscape is mature. Litigation risk would be more relevant if a sponsor launched a newly patented formulation and another applicant filed an abbreviated application with a Paragraph IV certification against that formulation patent.[3]

What patent litigation and settlement risks affect metoclopramide?

For the legacy product, patent litigation and settlement agreements are unlikely to determine market access. The commercial risk is more likely to arise from:

• Patent disputes over a new ODT, liquid, injectable, or modified-release formulation.
• Written-description and obviousness challenges involving excipient combinations.
• Drug-device claims covering oral syringes or prefilled injection systems.
• Manufacturing-process patents.
• Trade-secret disputes involving taste masking or stability systems.
• ANDA litigation triggered by a later formulation patent.

Settlement agreements involving a new metoclopramide product would require review for launch dates, licenses, authorized generic rights, supply obligations, and restrictions on formulation changes. No settlement should be treated as relevant to the legacy Reglan market without product-specific evidence.

How strong is the patent estate for a new metoclopramide formulation?

A new metoclopramide formulation could have moderate patent strength if it combines a genuine technical problem with measurable performance advantages. Stronger claims would generally cover a defined composition, concentration range, process, or dosage form linked to data.

Potentially stronger claim areas include:

• A taste-masking matrix that delivers a defined dissolution profile.
• A stable concentrated oral solution with demonstrated shelf-life performance.
• A preservative-free injectable composition with improved stability.
• A drug-device combination that improves dose accuracy.
• A modified-release system that produces a clinically useful exposure profile without increasing adverse effects.

Weak claims would include routine substitution of one filler, sweetener, flavor, or lubricant without unexpected performance. Formulation patents must also survive obviousness attacks based on known metoclopramide products and conventional excipient practice.

What generic entry risks exist for a new Reglan formulation?

Generic entry risk depends on whether the product is a simple pharmaceutical equivalent or a differentiated product requiring additional clinical or formulation data.

Product concept	Generic-entry risk	Main defense
Conventional tablet	High	Low-cost manufacturing and distribution
Standard oral solution	High	Palatability, device, and supply reliability
Taste-masked liquid	Moderate	Composition and performance patents
ODT	Moderate to high	Clinical usability and formulation claims
Preservative-free injection	Moderate	Container, stability, and manufacturing patents
Modified-release product	Moderate	Release-profile and clinical differentiation
New indication	Depends on claim scope	Method-of-use patents and regulatory exclusivity

A sponsor should expect price pressure unless it secures a product-specific advantage. The best defense combines a formulation patent, a device or packaging patent where appropriate, regulatory exclusivity, and a market segment that values reliability over lowest acquisition cost.

How does Reglan compare with competing antiemetic and prokinetic products?

Metoclopramide competes across several clinical and commercial categories.

Product category	Relative advantage versus metoclopramide	Relative limitation
Ondansetron and other 5-HT3 antagonists	Strong antiemetic positioning	Do not provide the same prokinetic effect
Domperidone, where available	Lower central nervous system penetration	Regulatory availability is limited in the United States
Erythromycin	Prokinetic activity	Tachyphylaxis and drug-interaction concerns
Prucalopride and other motility agents	Alternative motility mechanisms	Different indications and reimbursement profiles
Compounded formulations	Flexible dosing and flavoring	Variable quality and lack of standardized approval
Generic metoclopramide	Low price and broad availability	Limited differentiation and potential tolerability concerns

The commercial case for an improved metoclopramide product is strongest where the formulation solves a practical administration problem that competing products do not address.

What commercial opportunities exist for metoclopramide excipients?

The opportunity is concentrated in specialty and institutional segments rather than broad branded primary care.

Highest-priority opportunities

1. A palatable, ready-to-use oral liquid with a dosing syringe.
2. A preservative-free, ready-to-administer injection.
3. An ODT with validated taste masking and rapid disintegration.
4. A concentrated liquid designed for low administration volume.
5. A formulation compatible with enteral feeding tubes.
6. A stable product suitable for hospital shortage mitigation.

Revenue exposure

Revenue exposure is likely to be limited for a conventional branded tablet because generic pricing is entrenched. A differentiated product could support higher pricing if it reduces hospital preparation costs, improves adherence, limits compounding, or addresses an under-served administration population.

The most attractive buyer groups are hospitals, specialty pharmacies, long-term-care facilities, home-health providers, and caregivers managing patients with dysphagia or enteral feeding requirements. Broad retail substitution is less attractive because generic metoclopramide is inexpensive and familiar.

What manufacturing and geographic IP barriers apply?

Manufacturing barriers are more important than legacy composition-of-matter patents. Key barriers include:

• Sterile manufacturing capacity for injectable products.
• Aseptic filling and container-closure validation.
• Taste-masking process control.
• Low-dose content uniformity.
• Stability in concentrated solutions.
• Compatibility with enteral tubes and oral syringes.
• Supplier qualification for pharmaceutical-grade flavors and polymers.
• Control of extractables and leachables.

Geographic patent protection would depend on new filings. A sponsor could pursue composition, process, device, and use claims in the United States, Europe, Japan, and other commercially relevant markets. Legacy metoclopramide protection does not create a broad global barrier. Product availability, local registration requirements, and pricing controls may matter more than patent rights outside the United States.

Key Takeaways

• Reglan is a legacy metoclopramide brand with no meaningful original-product exclusivity.
• Generic tablets, solutions, and injections create high price pressure.
• Excipient innovation has the greatest value in taste masking, low-volume dosing, preservative-free injection, ODT delivery, and enteral administration.
• A new product would likely require a 505(b)(2) strategy or another pathway supported by formulation and clinical data.
• Conventional excipient substitutions are unlikely to produce strong patent protection.
• Stronger IP could cover defined compositions, release profiles, manufacturing processes, devices, or validated stability advantages.
• The boxed warning for tardive dyskinesia limits the commercial value of prolonged exposure and makes safety data central to any modified-release strategy.
• Hospital and specialty channels offer better commercial prospects than undifferentiated retail tablets.
• Manufacturing reliability, device integration, and product quality may create more defensible value than the active ingredient itself.

FAQs

Can a new flavor alone create a patentable Reglan product?

Usually not. A flavor system may support patentability only when it produces a measurable and non-obvious technical result, such as durable taste masking, improved stability, or superior dosing performance.

Is a metoclopramide oral solution suitable for pediatric commercialization?

It may be technically suitable for pediatric administration, but commercialization requires an approved pediatric indication, appropriate dosing evidence, safety assessment, and labeling. The drug’s neurological risks require particular attention.

Would a preservative-free Reglan injection qualify for a new patent?

It could, if the formulation provides a non-obvious stability, sterility, compatibility, or administration advantage. The absence of a preservative alone may be insufficient.

Can an excipient strategy reduce metoclopramide tardive dyskinesia risk?

Excipients can alter absorption and exposure, but they cannot be assumed to reduce tardive dyskinesia risk. Any safety claim would require clinical evidence and appropriate FDA review.

Is a Reglan 505(b)(2) product commercially attractive?

It can be attractive when it solves a clear administration or supply problem and supports defensible formulation or device IP. A conventional reformulation without meaningful clinical or operational value would face strong generic price competition.

References

1. U.S. Food and Drug Administration. (2019). Reglan (metoclopramide hydrochloride) tablets prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2009). FDA requires boxed warning for Reglan. FDA Drug Safety Communication.

3. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.